So far, large federal studies have shown no higher risk for major birth defects, miscarriage or other complications.

The Food and Drug Administration (FDA) has approved Bosaya ™ (denosumab-kyqq) and Aukelso ™ (denosumab-kyqq), biosimilars to Prolia ® (denosumab) and Xgeva ® (denosumab), respectively.

Garetosmab is a fully-human monoclonal antibody designed to bind and neutralize Activin A, a major promoter of HO in patients with FOP.

Findings show discomfort primarily exists among gynecologists seeing patients with a history of endometrial or epithelial ovarian cancer ...

The ACHIEVE-3 trial was a 52-week, randomized, open-label study that included 1698 T2D patients inadequately controlled on metformin.

Anifrolumab, a type I interferon receptor antagonist, is currently approved under the brand name Saphnelo for IV administration in the treatment of moderate to severe SLE.

US Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has said he plans to appoint as many as 7 new members. In June, Kennedy removed all 17 members of the panel, claiming it had ...

Factors tied to discontinuation included younger age, male sex, socioeconomic deprivation, higher comorbidity level.